Abstract
Background With cannabis legalization spreading to more countries for both medicinal and recreational use, grasping its effects on the human body is vital. The endocannabinoid system, governed by natural and external cannabinoid compounds, significantly impacts host metabolism. Working alongside the host’s immunomodulation, it shapes the gut microbiota, yielding benefits for the GI and immune systems.
Objective To assess the link between cannabis treatment and the gut/oral microbiome.
Methods We extensively searched PubMed, Embase, and Cochrane Library’s CENTRAL until December 9, 2023, for English studies involving adults with clinical abnormalities. Identified studies were analyzed, categorizing by different clinical aspects. Data was then qualitatively and quantitatively synthesized.
Result The study involved 10 studies encompassing 2511 participants, comprising 2 clinical trials and 8 observational studies. The review provided a range of microbiota by the influence of cannabis usage within different clinical contexts: HIV infection, pain/inflammation, systemic aspergillosis, obesity, cognitive deficits, and oral diseases. Users with anhedonia and HIV infection showed lower α-diversity, but those with knee arthritis showed higher α-diversity. According to research, 21.4% of MJ cigarette users experienced adverse outcomes; however, these lessened once they stopped smoking.
Conclusion These findings shed light on the complex effects of cannabis use on the human microbiota, underscoring the need for future research on the therapeutic potential of cannabis. This review provides valuable insights to guide future investigations in this field.
Registration ID PROSPERO 2022 CRD42022354331
Short Summary With the global expansion of cannabis legalization, understanding the effects of cannabis on the human body, particularly among individuals with diverse clinical conditions, is of paramount importance. Through a meticulous systematic review utilizing comprehensive data, our findings uncover that cannabis consumption in adults with varied clinical conditions leads to discernable alterations in the human microbiome. These noteworthy modifications necessitate careful consideration in future investigations exploring the potential beneficial or adverse effects of cannabis treatment on patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
M.T. was supported by the Graduate Scholarship Programme for ASEAN or Non-ASEAN Countries, and the Second Century Fund (C2F), Chulalongkorn University. T.O. and K.P. were funded by the Second Century Fund (C2F), Chulalongkorn University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Emails May Soe Thu, mst.maysoethu{at}gmail.com
Thunnicha Ondee, thunnichaon{at}yahoo.com
Szaye Rawicha Hall, szayehall01{at}outlook.com
Tanawin Nopsopon, tnopsopon{at}gmail.com
Ananya Jagota, ananyajagota{at}gmail.com
Nattiya Hirankarn, nattiyap{at}gmail.com
Joanne L. Fothergill, j.fothergill{at}liv.ac.uk
Barry J. Campbell, bjcampbl{at}liverpool.ac.uk
Krit Pongpirul. doctorkrit{at}gmail.com
Updated findings and authors.
Data Availability
All data produced in the present work are contained in the manuscript as supplementary files.
Abbreviations
- CENTRAL
- Cochrane Central Register of Controlled Trials
- CIs
- Confidence intervals
- GRADE
- Grading of Recommendation Assessment, Development and Evaluation
- NOS
- Newcastle - Ottawa Quality Assessment Scale
- PRISMA-P
- Preferred Reporting Items for Systematic review and Meta-analysis Protocols
- RCTs
- Randomized controlled trials
- ROBINS-I
- Risk Of Bias In Non-randomized Studies - of Interventions
- US
- United States.
